Home

Pfizer (PFE)

25.51
+0.00 (0.00%)
NYSE · Last Trade: Nov 12th, 6:37 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close25.51
Open-
Bid25.35
Ask25.36
Day's RangeN/A - N/A
52 Week Range20.92 - 27.69
Volume77,970
Market Cap143.03B
PE Ratio (TTM)14.83
EPS (TTM)1.7
Dividend & Yield1.720 (6.74%)
1 Month Average Volume81,428,151

Chart

About Pfizer (PFE)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More

News & Press Releases

Why Metsera's Share Price Is Plummeting This Weekfool.com
The biotech start-up's stock had been rising rapidly in 2025.
Via The Motley Fool · November 12, 2025
3 Unprofitable Stocks That Concern Us
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Via StockStory · November 11, 2025
1 Large-Cap Stock for Long-Term Investors and 2 We Turn Down
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Via StockStory · November 11, 2025
‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenariosstocktwits.com
Via Stocktwits · November 11, 2025
Pfizer CEO Reportedly Drops F-Bomb On Live TV Discussing Seagen, Metsera Dealsstocktwits.com
Via Stocktwits · November 10, 2025
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. 
Via StockStory · November 11, 2025
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In Indiabenzinga.com
Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.
Via Benzinga · November 11, 2025
Most active S&P500 stocks in Tuesday's sessionchartmill.com
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · November 11, 2025
Curious about the most active stocks on Tuesday?chartmill.com
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · November 11, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · November 11, 2025
Where Will Pfizer Be in 3 Years?fool.com
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.
Via The Motley Fool · November 11, 2025
AI Takes Center Stage: LogiPharma Report Reveals Pharmaceutical Supply Chains Embrace Intelligent Automation
The pharmaceutical industry, long known for its meticulous processes and stringent regulations, is undergoing a profound transformation driven by Artificial Intelligence. A recent LogiPharma AI Report underscores a significant shift, indicating that AI is no longer a peripheral tool but a strategic imperative for optimizing complex pharmaceutical supply chains. This pivotal report highlights a sector [...]
Via TokenRing AI · November 11, 2025
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?fool.com
Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.
Via The Motley Fool · November 11, 2025
Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaringfool.com
Pfizer not only beat expectations last quarter, but also boosted its guidance.
Via The Motley Fool · November 11, 2025
Shutdown Deal Breathes New Life Into Wall Streetchartmill.com
The prospect of a quick end to the US government shutdown has rekindled investor confidence. Tech rebounds, semiconductors sprint ahead, and insurers feel political pressure building. Meanwhile, all eyes shift toward the last major earnings report of the season: Nvidia.
Via Chartmill · November 11, 2025
The Top 5 Analyst Questions From Pfizer’s Q3 Earnings Call
Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth in non-COVID products and disciplined cost management as key drivers of performance. CEO Albert Bourla emphasized the company’s ability to deliver adjusted earnings above expectations, noting, “Our business is performing well, and we are raising the range of our adjusted diluted EPS guidance for full year 2025.” The quarter saw operational declines in legacy COVID-19 products, but new launches and established brands like Vyndaqel and Nurtec offset some of the softness, supported by ongoing productivity improvements and a focus on high-priority therapeutic areas.
Via StockStory · November 11, 2025
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers and some providers, faced considerable downward pressure. This divergence highlights a sector grappling with a flurry of groundbreaking drug
Via MarketMinute · November 10, 2025
Market Resilience Tested: How Investors Can Navigate U.S. Government Shutdowns
As the U.S. political landscape continues to present its unique set of challenges, the specter of a government shutdown remains a perennial concern for investors. These periods, marked by a cessation of non-essential federal operations due to budgetary impasses, inject a significant degree of political uncertainty into the financial
Via MarketMinute · November 10, 2025
Wall Street Cheers as Senate Vote Signals End to Record-Breaking US Government Impasse
Global equity markets have surged in early November 2025, fueled by renewed optimism that the United States government's historic shutdown, which commenced on October 1, 2025, may finally be nearing its conclusion. The protracted impasse, now the longest in the nation's history, has cast a shadow of uncertainty over the
Via MarketMinute · November 10, 2025
Looking for the most active stocks in the S&P500 index on Monday?chartmill.com
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · November 10, 2025
These stocks are the most active in today's sessionchartmill.com
Monday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!
Via Chartmill · November 10, 2025
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable tension between investor optimism and concerns over valuation. As of November 2025, the AI market stands at a pivotal juncture, with a concentrated surge in mega-cap AI players driving overall market [...]
Via TokenRing AI · November 10, 2025
Markets Breathe Sigh of Relief as Historic Government Shutdown Nears Resolution
Washington D.C. – November 10, 2025 – The United States stock market is experiencing a significant uplift today, as news of an impending resolution to the nation's longest-ever government shutdown sends a wave of positive sentiment across financial markets. After weeks of political deadlock, a bipartisan agreement in the Senate has
Via MarketMinute · November 10, 2025
Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trialbenzinga.com
Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIST trial.
Via Benzinga · November 10, 2025
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billioninvestors.com
The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote.
Via Investor's Business Daily · November 10, 2025